Table 4A.
Influence of demographic factors.
| tIgE(KU/L) | CSMS without omalizumab | CSMS with omalizumab | CSMS improvement | Recovery rate1 | |
|---|---|---|---|---|---|
| Gender | |||||
| Female(n=34) | 158.0[69.4,349.0] | 4.42[3.29,5.00] | 0.59[0.00,2.00] | 3.01 ± 0.24 | 10(29.4%) |
| Male(n=30) | 144.0[117.0,504.8] | 3.17[2.75,4.92] | 1.00[0.00,1.67] | 2.46 ± 0.26 | 9(33.3%) |
| P-value | 0.538 | 0.040 | 0.754 | 0.120 | 0.959 |
| Age2 | |||||
| 6-18 years old (n=13) | 225.0[115.5,576.5] | 3.67[2.75,5.00] | 1.00[0.00,1.67] | 2.61 ± 1.42 | 4(36.4%) |
| ≥18 years old (n=51) | 132.0[78.1,277.3] | 4.09[2.96,4.87] | 0.67[0.00,1.87] | 2.78 ± 1.43 | 15(29.4%) |
| P-value | 0.324 | 0.762 | 0.872 | 0.705 | 1.000 |